<DOC>
	<DOCNO>NCT02686346</DOCNO>
	<brief_summary>This study design phase Ib/II trial . The first part ( phase Ib ) dose escalation design explore safety ass recommend phase 2 dose Brentuximab Vedotin Hodgkin lymphoma patient treat ICE regimen . The second part , depend select dose completion phase Ib part study , explore safety addition efficacy recommend dose Brentuximab Vedotin select population patient treat ICE Hodgkin lymphoma .</brief_summary>
	<brief_title>Brentuximab Vedotin Refractory/Relapsed Hodgkin Lymphoma Treated ICE</brief_title>
	<detailed_description>PHASE I : 3 cycle Brentuximab Vedotin ICE every 3 week one cycle Brentuximab Vedotin alone dose describe . Cohorts three six evaluable patient recruit dose level . Dose escalation rule : Treat 3 patient level K 1 . If 0 patient experience dose-limiting toxicity ( DLT ) , escalate dose K+1 2 . If 2 patient experience DLT , de-escalate level K-1 3 . If 1 patient experience DLT , treat 3 patient dose level K A . If 1 6 experience DLT , escalate dose level K+1 B . If 2 6 experience DLT , de-escalate level K-1 Dose escalation begin level K. Level K : Brentuximab Vedotin : 1.2 mg/kg ( cycle 1-3 ) , 1.8 mg/kg ( cycle 4 ) ICE ( cycle 1-3 ) : Etoposide 100 mg/m² ( day1 3 ) ; Carboplatine max 800mg ( day 2 ) ; Ifosfamide + Mesna 5 g/m² ( day 2 ) Level K -1 : Brentuximab Vedotin : 0.8 mg/kg ( cycle 1-3 ) , 1.8 mg/kg ( cycle 4 ) ICE ( cycle 1-3 ) : Etoposide 100 mg/m² ( day1 3 ) ; Carboplatine max 800mg ( day 2 ) ; Ifosfamide + Mesna 5 g/m² ( day 2 ) Level K +1 : Brentuximab Vedotin : 1.8 mg/kg ( cycle 1-3 ) , 1.8 mg/kg ( cycle 4 ) ICE ( cycle 1-3 ) : Etoposide 100 mg/m² ( day1 3 ) ; Carboplatine max 800mg ( day 2 ) ; Ifosfamide + Mesna 5 g/m² ( day 2 ) Dose find rule : Provisional dose level list previous table . Dose-escalation continue Maximal Tolerated Dose ( MTD ) Recommended Phase 2 Dose ( RP2D ) reach full dos BV ICE deliver without DLT PHASE II : 3 cycle Brentuximab Vedotin + ICE every 3 week one cycle Brentuximab Vedotin alone . The recommend dose BV ICE determine phase I Brentuximab Vedotin : MTD mg/kg ( cycle 1-3 ) , 1.8 mg/kg ( cycle 4 ) ICE ( cycle 1-3 ) : Etoposide 100 mg/m² ( day1 3 ) ; Carboplatine max 800mg ( day 2 ) ; Ifosfamide + Mesna 5 g/m² ( day 2 ) The recommend dose BV ICE determine phase I .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm cluster differentiation antigen 30 + ( CD30+ ) HL , primarily refractory first line chemotherapy first relapse polychemotherapy regimen Measurable disease define least one single node tumor lesion CT scan &gt; 1.5 cm Fluorodeoxyglucose ( FDG ) PET/ CT realize relapse positive . Age ≥ 18 year 65 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 ( see appendix 19.5 ) Life expectancy &gt; 3 month treatment No major organ dysfunction , unless HLrelated Normal cardiac pulmonary function auto transplantation Total bilirubin &lt; 1.5 x ULN ( unless due lymphoma involvement liver know history Gilbert 's syndrome ) Alanine aminotransferase/aspartate aminotransferase ( ALT/AST ) ≤ 2 x ULN ( unless due lymphoma involvement liver : ≤ 5 x ULN ) Creatinine clearance &gt; 60 mL/min Absolute neutrophil count ≥ 1.5x109/L , unless cause diffuse bone marrow infiltration HL Platelets ≥ 100x109/L , unless cause diffuse bone marrow infiltration HL Hemoglobin must ≥ 8g/dL Written inform consent Able adhere study visit schedule protocol requirement Eligible high dose chemotherapy autologous peripheral blood stem cell transplantation Resolution toxicity firstline therapy Female patient either postmenopausal least 1 year screen visit surgically sterile childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent 6 month last dose study drug , agree completely abstain heterosexual intercourse . Male patient , even surgically sterilize , ( i.e. , status post vasectomy ) agree practice effective barrier contraception entire study period 6 month last dose study drug , agree completely abstain heterosexual intercourse . Peripheral sensory motor neuropathy grade ≥ 2 Any chemotherapy , radiotherapy , immunotherapy investigational , therapy treatment lymphoma within 28 day prior Cycle1 Day1 Patient treat first line treatment brentuximab vedotin alone combination Female patient lactate breast feed positive serum pregnancy test screen period positive pregnancy test 4 day prior start study drug Patients active , uncontrolled infection ( require systemic antibiotic within two week prior treatment ) Prior history another cancer unless subject free disease ≥ 3 year ( exception nonmelanoma skin cancer , completely resect melanoma TNMpT1 carcinoma situ uterine cervix ) Known cerebral meningeal disease ( HL etiology ) , include sign symptom Progressive multifocal leukoencephalopathy Known hypersensitivity recombinant protein , murine protein , excipient contain drug formulation brentuximab vedotin . Known history human immunodeficiency virus ( HIV ) , know active Hepatitis C Virus , active Hepatitis B Virus ( HBV ) infection uncontrolled active systemic infection require intravenous ( IV ) antibiotic . Patients psychiatric disorder would preclude compliance drug delivery Patients severe and/or uncontrolled medical condition condition could affect participation study : 1. unstable angina pectoris , symptomatic congestive heart failure ( NYHA II , III , IV ) , myocardial infarction ≤ 2 year prior first study drug administration , serious uncontrolled cardiac arrhythmia , angina , electrocardiographic evidence acute ischemia active conduction system abnormalities 2. cerebrovascular accident ≤ 6 month study drug start recent evidence ( within 6 month first dose study drug ) 3. leftventricular ejection fraction &lt; 50 % 4. severely impaired pulmonary function define spirometry diffuse capacity lung carbon monoxide ( DLCO ) 50 % less normal predict value and/or O2 saturation 90 % less rest room air 5. active ( acute chronic ) uncontrolled disorder impair ability evaluate patient patient complete study 6. active systemic viral , bacterial , fungal infection require systemic antibiotic within 2 week prior first study drug dose 7. nonmalignant medical illness uncontrolled whose control may jeopardize study drug , severe hypertension control medical management thyroid abnormality thyroid function maintain normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>